

Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress

Communication of the detailed results of the first two stages of the clinical
study on the ¹⁸F-ODS2004436 radiotracer in lung cancer

Dijon, October 15, 2018, at 6:00pm CEST – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical company specializing in precision medicine, and Centre Georges François Leclerc (CGFL), a cancer research and treatment center in Burgundy, announced today the presentation of the detailed results of the first two stages of their clinical study on lung cancer at the 31st EANM Congress,¹ taking place on October 13-17, 2018, in Düsseldorf, Germany.

The annual EANM congress is the reference meeting in nuclear medicine, which attracts every year over 6,000 physicians and scientists from the public and private sectors. Prof. Alexandre Cochet, Head of the Department of Nuclear Medicine at CGFL and principal investigator of the study, will present the detailed results of the first two stages of the clinical study on the ¹⁸F-ODS2004436 radiotracer in lung cancer.

The objective of this Phase 1 clinical study is to assess the clinical relevance of the ¹⁸F-ODS2004436 radiotracer in PET imaging², by determining its sensitivity and specificity in patients with non-small cell lung cancer.

"This study illustrates the relevance and positioning of molecular imaging biomarkers in tumor characterization, a crucial step in the development of personalized medicine." **comments Professor Alexandre Cochet, the principal investigator of the study.**

"We are very pleased with the progress of the clinical study conducted with this molecular radiotracer, which paves the way for molecular biomarkers in pharmaco-imaging and fully validates the relevance of our Nanocyclix technology in precision medicine. We expect to complete the third stage of the Phase 1 by the end of this year. The sole objective of this third stage is to optimize the clinical protocol for the future Phase 3." **said Philippe GENNE, CEO and Founder of OncoDesign.**

Full details of Prof. Alexandre Cochet's presentation:

Author: Prof. Alexandre Cochet, CGFL, Dijon, France
Poster: OP-523
Session: 1308 – Clinical Oncology – Rapid Fire Session: Lung
Date: Tuesday, October 16, 2018
Time: 11:30am – 1:00pm (local time)
Location: Hall 4

¹ European Association of Nuclear Medicine

² Positron Emission Tomography, a standard clinical diagnostic technique

About Centre Georges François Leclerc: www.cgfl.fr

Founded in 1967, the expert referral center Centre Georges-François Leclerc (CGFL) is the only healthcare facility exclusively dedicated to oncology in the Burgundy / Franche-Comté region (between Paris and Lyon). In 50 years, it has become a cancer referral center treating over 22,000 patients each year using multiple innovative approaches: molecular medicine, genomics, immunotherapy, preclinical and clinical imaging, early development of new drugs, high-precision radiotherapy, outpatient surgery, quality of life, etc. Its team of physicians and researchers, recognized at the highest international level, offers personalized medicine and access to research that directly benefits patients through its state-of-the-art platforms. These platforms are listed in the University of Burgundy catalog, including one platform approved by the National Cancer Institute, CGFL's early clinical research platform (the only one available for the whole administrative region of eastern France). CGFL conducts research on advanced treatment personalization based on a comprehensive approach, from basic research to clinical stages. CGFL is the only institution in the region to prohibit its physicians from pursuing private practice with payment overruns, thereby offering all patients access to innovative care without having to pay anything. CGFL is a member of the Unicancer Group. With 800 employees, 50 researchers, 135 physicians, and an annual budget of €100 million, of which 10% is dedicated to research and innovation, CGFL is the 3rd cancer center in France in terms of number of patients included in clinical studies.

About ONCODESIGN: www.oncodesign.com

Founded over 20 years ago by Dr Philippe Genne, the Company's CEO and Chairman, Oncodesign is a biopharma company dedicated to the precision medicine. With its unique experience acquired by working with more than 600 clients, including the world's largest pharmaceutical companies, along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, regulated bioanalysis and medical imaging, Oncodesign is able to predict and identify, at a very early stage, each molecule's therapeutic usefulness and potential to become an effective drug. Applied to kinase inhibitors, which represent a market estimated at over \$46 billion in 2016 and accounting for almost 25% of the pharmaceutical industry's R&D expenditure, Oncodesign's technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, in oncology and elsewhere, along with partnerships with pharmaceutical groups such as Bristol-Myers Squibb and UCB. Oncodesign is based in Dijon, France, in the heart of the town's university and hospital hub, and within the Paris-Saclay cluster, Oncodesign has 227 employees and subsidiaries in Canada and the USA.

Contacts

Centre Georges François Leclerc

Carole DIOLOT
Director of Communication and Patronage
Tél. : +33 (0)3 80 73 75 54
cdiolot@cgfl.fr

NewCap

Investor Relations
Mathilde Bohin / Louis-Victor Delouvrier
Tél. : +33 (0)1 44 71 94 95
oncodesign@newcap.eu

NewCap

Media Relations
Arthur Rouillé
Tél. : +33 (0)1 44 71 00 15
oncodesign@newcap.eu

Oncodesign

Philippe Genne
Chairman and CEO
Tél. : +33 (0)3 80 78 82 60
investisseurs@oncodesign.com

